- Home
- DNUT vs TRVI Comparison
DNUT vs TRVI Comparison
Compare DNUT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- TRVI
- Stock Information
- Founded
- DNUT 1937
- TRVI 2011
- Country
- DNUT United States
- TRVI United States
- Employees
- DNUT N/A
- TRVI N/A
- Industry
- DNUT Food Chains
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- TRVI Health Care
- Exchange
- DNUT Nasdaq
- TRVI Nasdaq
- Market Cap
- DNUT 739.0M
- TRVI 629.8M
- IPO Year
- DNUT 2021
- TRVI 2019
- Fundamental
- Price
- DNUT $2.89
- TRVI $6.51
- Analyst Decision
- DNUT Buy
- TRVI Strong Buy
- Analyst Count
- DNUT 8
- TRVI 8
- Target Price
- DNUT $10.23
- TRVI $19.31
- AVG Volume (30 Days)
- DNUT 7.2M
- TRVI 1.0M
- Earning Date
- DNUT 05-08-2025
- TRVI 05-08-2025
- Dividend Yield
- DNUT 4.84%
- TRVI N/A
- EPS Growth
- DNUT N/A
- TRVI N/A
- EPS
- DNUT N/A
- TRVI N/A
- Revenue
- DNUT $1,597,883,000.00
- TRVI N/A
- Revenue This Year
- DNUT N/A
- TRVI N/A
- Revenue Next Year
- DNUT $3.61
- TRVI N/A
- P/E Ratio
- DNUT N/A
- TRVI N/A
- Revenue Growth
- DNUT N/A
- TRVI N/A
- 52 Week Low
- DNUT $2.58
- TRVI $2.30
- 52 Week High
- DNUT $12.68
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- DNUT 31.79
- TRVI 54.36
- Support Level
- DNUT $2.85
- TRVI $6.08
- Resistance Level
- DNUT $3.08
- TRVI $6.47
- Average True Range (ATR)
- DNUT 0.16
- TRVI 0.34
- MACD
- DNUT 0.03
- TRVI -0.02
- Stochastic Oscillator
- DNUT 17.65
- TRVI 67.01
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.